Free Trial
→ Top Wall Street investor warns of a “market chasm” (From Stansberry Research) (Ad)tc pixel

Matt Phipps Analyst Performance

Analyst at William Blair

Matt Phipps is a stock analyst at William Blair in the medical sector, covering 16 publicly traded companies. Over the past year, Matt Phipps has issued 6 stock ratings, including buy and hold recommendations. While full access to Matt Phipps' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Matt Phipps' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
35 Last 7 Years
Buy Recommendations
85.71% 30 Buy Ratings
Companies Covered
16 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy85.7%30 ratings
Hold14.3%5 ratings
Sell0.0%0 ratings

Out of 35 total stock ratings issued by Matt Phipps at William Blair, the majority (85.7%) have been Buy recommendations, followed by 14.3% Hold.

Best & Worst Calls

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
16 companies

Matt Phipps, an analyst at William Blair, currently covers 16 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
16 companies		100.0%

Matt Phipps of William Blair specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
11 companies		68.8%
PHARMACEUTICAL PREPARATIONS
3 companies		18.8%
MED - DRUGS
2 companies		12.5%

Matt Phipps' Ratings History at William Blair

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
Export to Excel
CompanyReport DateActionReport Date Price12-Month
Price Target		Rating12-Month
Price & ROI		Details
Insmed, Inc. stock logo
INSM
Insmed
8/20/2025Initiated Coverage$127.21Outperform
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
7/11/2025Downgrade$64.17Market Perform
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
7/7/2025Reiterated Rating$3.27Market Perform
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
4/21/2025Initiated Coverage$0.84Outperform
Xencor, Inc. stock logo
XNCR
Xencor
4/21/2025Initiated Coverage$9.70Outperform
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3/11/2025Upgrade$21.98Outperform
Today's Ratings
Top-Rated Stocks
More Ratings Tools